EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

BACKGROUND: In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical u...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Semmlinger, Anna, von Schoenfeldt, Viktoria, Wolf, Verena, Meuter, Alexandra, Kolben, Theresa Maria, Kolben, Thomas, Zeder-Goess, Christine, Weis, Florian, Gallwas, Julia, Wuerstlein, Rachel, Hermelink, Kerstin, Schmoeckel, Elisa, Harbeck, Nadia, Mayr, Doris, Mahner, Sven, Jeschke, Udo, Ditsch, Nina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902996/
https://ncbi.nlm.nih.gov/pubmed/29661238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4286-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars